October 10, 2012
CMS is reconsidering Section 220.6 of the National Coverage Determination (NCD) Manual pursuant to a request from the Eli Lilly and Company that coverage for PET tracers be expanded to include those agents that image beta-amyloid plaques in the context of the diagnosis of dementia. CMS is soliciting public comment relevant to this request, particularly those that include scientific evidence.
CMS opened the public comment period on October 9, 2012, which will last 30 days, ending on Thursday, November 8, 2012.
For more information, please visit the CMS announcement.